A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

Sponsor
Genentech, Inc.
Study ID
NCT00954642
Phase
PHASE1
Status
Completed

Conditions

  • Solid Cancers

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — DRUG
    Intravenous repeating dose
  • MNRP1685A — DRUG
    Escalating intravenous dose
  • paclitaxel — DRUG
    Intravenous repeating dose

Study Details

This is a Phase Ib, open-label, dose-escalation study of MNRP1685A given by intravenous (IV) infusion as therapy for locally advanced or metastatic solid tumors.

Key Dates

First listed
Aug 7, 2009
Start date
Aug 31, 2009
Status verified
May 2017
Primary completion
Dec 31, 2011
Completion
Dec 31, 2011

Study Design

Enrollment
24 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: A
  • Experimental: B

Primary Outcome Measure

Incidence and nature of dose-limiting toxicities (DLTs) [ Time Frame: Through study completion or early study discontinuation ]

Related Studies